Skip Navigation
Find a Doctor
 
 
 
 

 

Search for
other physicians or researchers.

Find a Doctor
Photo of Dr. Yvette Kasamon

Yvette Leslie Kasamon, MD

Associate Professor of Oncology
Female
Appointment Phone

410-955-8964

Primary Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Associate Professor of Oncology
  • Associate Professor of Medicine

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center

Expertise

Allogeneic Bone Marrow Transplantation, Bone Marrow Transplantation/ Stem Cell Transplantation, Chronic Lymphoblastic Leukemia, Hodgkin's Disease, Lymphoma, Medical Oncology, Non-Hodgkin's Lymphoma

Research Interests

Clinical investigation of Hodgkin's and non-Hodgkin's lymphoma

Languages

  • English
  • Polish

Clinical Trial Keywords

  • Lymphoma
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Disease

Additional Resources

Additional Resources +
  • Education +

    Training

    • University of Pittsburgh School of Medicine ( Pittsburgh PA ) (1999)

    Residencies

    • Brigham and Women's Hospital/Internal Medicine ( Boston MA ) (2002)

    Fellowships

    • The Johns Hopkins Hospital/Oncology and Hematology ( Baltimore MD ) (2005)

    Certifications

    • Internal Medicine, American Board of Internal Medicine (2012)
    • Hematology, American Board of Internal Medicine (2005)
    • Medical Oncology, American Board of Internal Medicine (2005)
  • Research & Publications +

    Research Summary

    Dr. Kasamon is a clinical researcher in lymphoma and in bone marrow transplantation. She has a dedicated lymphoma clinic and develops clinical trials for patients with hematologic malignancies. She has served as Chair of the Johns Hopkins Clinical Research Review Committee, through which oncology studies undergo scientific review.

    Selected Publications

    1. Bolanos-Meade, J.; Garrett-Mayer, E.; Luznik, L.; Anders, V.; Webb, J.; Fuchs, E.J.; Huff, C.A.; Matsui, W.; Borrello, I.M.; Brodsky, R.; Kasamon, Y.L.; Swinnen, L.J.; Flinn, I.W.; Ambinder, R.F.; Jones, R.J.; Hess, A.D.; Vogelsang, G.B. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-1191.
    2. Kasamon, Y.L. Blood or marrow transplantation for mantle cell lymphoma. Curr Opin Oncol. 2007 Mar;19(2):128-135.
    3. Kasamon, Y.L.; Flinn, I.W. Management of symptomatic, untreated chronic lymphocytic leukemia. Blood Rev. 2007 May;21(3):143-156.
    4. Kasamon, Y.L.; Jones, R.J.; Wahl, R.L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007 Jan;48 Suppl 1:19S-27S.
    5. Kasamon, Y.L.; Ambinder, R.F. Immunotherapies for Hodgkin''s lymphoma. Critical reviews in oncology/hematology. 2008 May;66(2):135-144.
    6. Kasamon, Y.L.; Wahl, R.L. FDG PET and risk-adapted therapy in Hodgkin''s and non-Hodgkin''s lymphoma. Curr Opin Oncol. 2008 Mar;20(2):206-219.
    7. Swinnen, L.J.; LeBlanc, M.; Grogan, T.M.; Gordon, L.I.; Stiff, P.J.; Miller, A.M.; Kasamon, Y.; Miller, T.P.; Fisher, R.I. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008 Jul 27;86(2):215-222.
    8. Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.
    9. Jones, R.J.; Gocke, C.D.; Kasamon, Y.L.; Miller, C.B.; Perkins, B.; Barber, J.P.; Vala, M.S.; Gerber, J.M.; Gellert, L.L.; Siedner, M.; Lemas, M.V.; Brennan, S.; Ambinder, R.F.; Matsui, W. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 2009 Jun 4;113(23):5920-5926.
    10. Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O''Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biol Blood Marrow Transplant. 2009 Nov 16.
    11. Kasamon, Y.L.; Wahl, R.L.; Ziessman, H.A.; Blackford, A.L.; Goodman, S.N.; Fidyk, C.A.; Rogers, K.M.; Bolanos-Meade, J.; Borowitz, M.J.; Ambinder, R.F.; Jones, R.J.; Swinnen, L.J. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009 Feb;15(2):242-248.
    12. Kasamon, Y.L.; Jones, R.J.; Brodsky, R.A.; Fuchs, E.J.; Matsui, W.; Luznik, L.; Powell, J.D.; Blackford, A.L.; Goodrich, A.; Gocke, C.D.; Abrams, R.A.; Ambinder, R.F.; Flinn, I.W. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol. 2010 Jun;21(6):1203-1210.
    13. Kasamon, Y.L.; Jones, R.J.; Gocke, C.D.; Blackford, A.L.; Seifter, E.J.; Davis-Sproul, J.M.; Gore, S.D.; Ambinder, R.F. Extended Follow-Up of Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide (4-HC) Purging for Indolent or Transformed Non-Hodgkin''s Lymphomas. Biol Blood Marrow Transplant. 2010 Jul 21.
    14. Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O''Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr;16(4):482-489.
    15. Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.
    16. Smith, B.D.; Kasamon, Y.L.; Kowalski, J.; Gocke, C.; Murphy, K.; Miller, C.B.; Garrett-Mayer, E.; Tsai, H.L.; Qin, L.; Chia, C.; Biedrzycki, B.; Harding, T.C.; Tu, G.H.; Jones, R.; Hege, K.; Levitsky, H.I. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010 Jan 1;16(1):338-347.
    17. Kasamon, Y.L. Prognostication and Risk-Adapted Therapy of Hodgkin''s Lymphoma Using Positron Emission Tomography. Adv Hematol. 2011;2011:271595.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Upcoming Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 41-955-8839
    Appointment Phone: 410-955-8964
    Fax: 410-955-8587
    Location Map

    Department/Division

    • Oncology
    • Medicine

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer